Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition for preventing or treating cervical cancer including gypenoside lxxv

A technology of Gynostemma saponin and composition, which is applied in the field of compositions for preventing or treating cervical cancer containing Gynostemma saponin LXXV, and can solve the problems such as the pharmacological activity effect of Gynostemma saponin on cervical cancer that is not yet known

Inactive Publication Date: 2017-08-18
INTELLIGENT SYNTHETIC BIOLOGY CENT
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Many efforts have been made to clarify the pharmacological use of these gypenosides. It is known that gypenosides isolated from gypenosides have skin whitening or hair growth promoting effects (Korean Laid-open Patent No. 10-2008-0085292), gynosides isolated from gypenoside extracts Gypenoside has therapeutic or preventive effect on type II diabetes, obesity or hyperlipidemia (Korean Laid-Open Patent No. 10-2013-0069430), and colitis therapeutic or preventive effect of Gypenoside (Korean Laid-Open Patent No. 10-2012- 0005896), but the pharmacological activity effect of said gypenoside on cervical cancer is not yet known

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating cervical cancer including gypenoside lxxv
  • Composition for preventing or treating cervical cancer including gypenoside lxxv
  • Composition for preventing or treating cervical cancer including gypenoside lxxv

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1. Separation and Analysis of Gypenoside LXXV (Gypenoside LXXV)

[0055] Gypenoside LXXV (GypLXXV), Gypenoside XVII (GypXVII), Ginsenoside Rb 1 (Rb1) and 20(S)-ginsenoside-Rg3(Rg3(S)), for the separation of the compounds, HPLC (High performance liquid chromatography) and LC / MS / MS (liquid chromatography-secondary mass spectrometry) were implemented )analyze.

[0056] For HPLC analysis, an HPLC system (Younglin Co., Ltd. (Yinglin Co., Ltd.), Korea) including a quaternary pump, an autoinjector, and a single-wavelength ultraviolet detector (730D) was used, and AutoChro3000 software from Younglin Company was used to implement Confirmation and integration of chromatographic peaks. Ginsenosides were separated using a guard column (Eclipse XDB C 18 , 5μm, 12.5×4.6mm i.d.) and Prodigy ODS(2)C 18 Columns (5 μm, 150×4.6 mm i.d., Phenomenex (Philomen Corporation), USA) were implemented. The mobile phase is composed of acetonitrile solvent A and distilled water solvent ...

Embodiment 2

[0059] Example 2. Cytotoxic effect of gypenoside LXXV in HeLa cells

[0060] In order to demonstrate the cytotoxic effect of GypLXXV in tumor cells, the cervical cancer cell line HeLa was used to compare the effect of Rb on cell viability. 1, GypXVII, Rg3(S) and GypLXXV cytotoxic effects.

[0061] In DMEM (Dulbecco's Modified Eagle's Medium, Dulbecco's Modified Eagle's Medium, containing 10% FBS, 2mmol / L glutamic acid (glutamine), 100U / mL penicillin (penicillin) and 100mg / mL streptomycin (streptomycin), Dulbecco's Modified Eagle's Medium Er culture medium) medium, at 37 ℃ containing 5% CO 2 HeLa cells were cultured under conditions. GypLXXV contained in DMSO (dimethyl sulfoxide) was adjusted to the final concentration described, and an appropriate amount was added to the medium.

[0062] Analysis of CellTiter by MTT (dimethyl thiazolyl-2,5-diphenyltetrazolium bromide, thiazolyl blue) Non-Radioactive Cell Proliferation Assay kit (non-radioactive cell proliferation assay ki...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition including, as an active ingredient, Gypenoside LXXV or a pharmaceutically acceptable salt thereof for preventing or treating cervical cancer, a method for preventing or treating cervical cancer comprising a step of administering the pharmaceutical composition to a non-human subject, a health functional food including, as an active ingredient, Gypenoside LXXV for preventing or alleviating cervical cancer, and a feed composition including, as an active ingredient, Gypenoside LXXV for preventing or alleviating cervical cancer.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of cervical cancer containing Gynostemma LXXV or a pharmaceutically acceptable salt thereof as an active ingredient; prevention including the step of administering the pharmaceutical composition to an individual other than a human body Or a method for treating cervical cancer; a health functional food composition for preventing or improving cervical cancer containing gypenoside LXXV as an active ingredient; and a feed composition for preventing or improving cervical cancer containing gypenoside LXXV as an active ingredient. Background technique [0002] Gypenoside (Gyp) is known to be a triterpene saponin mainly contained in Gynostemma pentaphyllum, and its structure and physiological activity are almost similar to those of ginsenoside. So far, more than 100 kinds of gypenosides including gypenoside LXXV and gypenoside XVII have been known. [0003] Many effo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00A23L33/11A23K20/121
CPCA61K31/704A23V2002/00A23V2200/308A23V2250/612A23V2250/61A23V2250/628A23V2250/642A23V2250/6418A23V2250/6422A23V2250/6402A23V2250/6416A23V2250/5118A23V2250/5026A23V2250/5432A23V2250/5108A23V2250/51084A23V2250/1578A23V2250/161A23V2250/18A23V2250/2124A61P35/00A23L33/10
Inventor 崔昌浩林完泽金善昌
Owner INTELLIGENT SYNTHETIC BIOLOGY CENT